QR-Code

Cycloguanil and Analogues Potently Target DHFR in Cancer Cells to Elicit Anti-Cancer Activity

Dihydrofolate reductase (DHFR) is an established anti-cancer drug target whose inhibition disrupts folate metabolism and STAT3-dependent gene expression. Cycloguanil was proposed as a DHFR inhibitor in the 1950s and is the active metabolite of clinically approved <i>plasmodium</i> DHFR inhibitor Pro...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Jennifer I. Brown, Peng Wang, Alan Y. L. Wong, Boryana Petrova, Rosanne Persaud, Sepideh Soukhtehzari, Melanie Lopez McDonald, Danielle Hanke, Josephine Christensen, Petar Iliev, Weiyuan Wang, Daniel K. Everton, Karla C. Williams, David A. Frank, Naama Kanarek, Brent D. G. Page
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2023-01-01
Schriftenreihe:Metabolites
Schlagworte:
dihydrofolate reductase
folate metabolism
target engagement
cancer therapy
cycloguanil
breast cancer
Online-Zugang:https://www.mdpi.com/2218-1989/13/2/151
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge